Kodiak Sciences Statistics
Total Valuation
Kodiak Sciences has a market cap or net worth of $978.18 million. The enterprise value is $899.17 million.
Important Dates
The next estimated earnings date is Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Kodiak Sciences has 52.70 million shares outstanding. The number of shares has increased by 0.38% in one year.
| Current Share Class | 52.70M |
| Shares Outstanding | 52.70M |
| Shares Change (YoY) | +0.38% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 5.53% |
| Owned by Institutions (%) | 45.95% |
| Float | 29.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 13.59 |
| P/TBV Ratio | 13.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.48, with a Debt / Equity ratio of 0.93.
| Current Ratio | 3.48 |
| Quick Ratio | 3.36 |
| Debt / Equity | 0.93 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -140.33% and return on invested capital (ROIC) is -60.89%.
| Return on Equity (ROE) | -140.33% |
| Return on Assets (ROA) | -39.38% |
| Return on Invested Capital (ROIC) | -60.89% |
| Return on Capital Employed (ROCE) | -91.88% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.83M |
| Employee Count | 109 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +369.79% in the last 52 weeks. The beta is 2.68, so Kodiak Sciences's price volatility has been higher than the market average.
| Beta (5Y) | 2.68 |
| 52-Week Price Change | +369.79% |
| 50-Day Moving Average | 13.45 |
| 200-Day Moving Average | 6.98 |
| Relative Strength Index (RSI) | 56.63 |
| Average Volume (20 Days) | 967,969 |
Short Selling Information
The latest short interest is 3.80 million, so 7.20% of the outstanding shares have been sold short.
| Short Interest | 3.80M |
| Short Previous Month | 3.81M |
| Short % of Shares Out | 7.20% |
| Short % of Float | 12.86% |
| Short Ratio (days to cover) | 3.54 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -207.39M |
| Pretax Income | -199.83M |
| Net Income | -199.83M |
| EBITDA | -188.89M |
| EBIT | -207.39M |
| Earnings Per Share (EPS) | -$3.79 |
Full Income Statement Balance Sheet
The company has $104.17 million in cash and $65.21 million in debt, giving a net cash position of $38.95 million or $0.74 per share.
| Cash & Cash Equivalents | 104.17M |
| Total Debt | 65.21M |
| Net Cash | 38.95M |
| Net Cash Per Share | $0.74 |
| Equity (Book Value) | 70.29M |
| Book Value Per Share | 1.33 |
| Working Capital | 76.91M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$114.98 million and capital expenditures -$732,000, giving a free cash flow of -$115.71 million.
| Operating Cash Flow | -114.98M |
| Capital Expenditures | -732,000 |
| Free Cash Flow | -115.71M |
| FCF Per Share | -$2.20 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kodiak Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.38% |
| Shareholder Yield | -0.38% |
| Earnings Yield | -21.30% |
| FCF Yield | -12.33% |
Analyst Forecast
The average price target for Kodiak Sciences is $19.29, which is 3.93% higher than the current price. The consensus rating is "Buy".
| Price Target | $19.29 |
| Price Target Difference | 3.93% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -32.79% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |